Money
Filter News
Found 83,198 articles
-
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 29, 2023
12/29/2023
Pyxis Oncology, Inc. reported that Pyxis Oncology’s Compensation Committee of the Board of Directors approved a stock option grant to Ken Kobayashi, M.D., the Company’s newly appointed Chief Medical Officer, in connection with his employment with the Company effective on November 27, 2023.
-
SomaLogic Board Reiterates Value-Maximizing Transaction with Standard BioTools is in Best Interests of All Stockholders
12/29/2023
SomaLogic, Inc., a leader in proteomics technology, sent the following open letter to stockholders reiterating the Board's belief that the proposed transaction between SomaLogic and Standard BioTools is in the best interest of all stockholders.
-
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - December 29, 2023
12/29/2023
Arrowhead Pharmaceuticals, Inc. announced that as an inducement to entering into employment with the Company, on December 28, 2023, the Company’s Board of Directors approved “inducement” grants to 32 new employees under Rule 5635 of the NASDAQ Listing Rules.
-
MedMira Reports First Quarter Results FY2024
12/29/2023
MedMira Inc., reported on its financial results for the quarter ended October 31, 2023.
-
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - December 29, 2023
12/29/2023
IDEAYA Biosciences, Inc. announced that, on December 28, 2023, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 18,500 shares of the Company's common stock to a newly hired employee.
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 29, 2023
12/29/2023
Sarepta Therapeutics, Inc. granted equity awards on December 29, 2023 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 4 individuals hired by Sarepta in December 2023.
-
Antibe Announces Early Warrant Exercise Incentive Program - December 29, 2023
12/29/2023
Antibe Therapeutics Inc. is pleased to announce an Early Warrant Exercise Incentive Program for its 6.5 million outstanding and unlisted share purchase warrants having an exercise price of $1.50 and expiring on July 31, 2024.
-
Heranova Lifesciences Debuts with $13.5 Million Seed and Seed+ Round Funding to Offer Integrated Clinical Solutions to Women's Health
12/28/2023
Heranova Lifesciences Holding Ltd. announced the successful completion of a USD 13.5 million seed and seed+ financing to develop and offer integrated Women's Health solutions worldwide.
-
Titan Pharmaceuticals Announces Reverse Stock Split and Ratio - December 28, 2023
12/28/2023
Titan Pharmaceuticals, Inc. announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company's common stock, which will be effective following the filing of an amendment to the Company’s Amended and Restated Certificate of Incorporation.
-
Inspira™ Technologies Closes on $3.88 Million Registered Direct Offering
12/28/2023
Inspira Technologies OXY BHN Ltd. announces the closing of its previously announced registered direct offering of 3,031,250 ordinary shares, at a purchase price of $1.28 per ordinary share.
-
Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering
12/28/2023
Bluejay Diagnostics, Inc. announced the pricing of a public offering of 2,692,308 shares of the Company’s common stock and warrants to purchase up to 2,692,308 shares of common stock at a combined offering price of $1.30 per share and associated warrant.
-
MIMEDX Announces Conversion of Outstanding Series B Convertible Preferred Stock to Common Stock
12/28/2023
MiMedx Group, Inc. announced that its outstanding 95,000 shares of Series B Convertible Preferred Stock, together with any accrued dividends, were automatically converted into shares of the Company’s Common Stock on December 22, 2023, in accordance with the Preferred Stock terms set forth in the Company’s Articles of Incorporation.
-
Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise
12/28/2023
Trevena, Inc. announced that it has closed its previously announced offering for the issuance and sale of 2,779,906 shares of common stock of Trevena and warrants to purchase up to an aggregate of 2,779,906 shares of common stock of Trevena, at a purchase price of $0.70 per share and associated warrant in a private placement, for gross proceeds to the Company of approximately $1.946 million.
-
Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn’s and Colitis Foundation for Development of PALI-2108
12/28/2023
Palisade Bio, Inc. announced the receipt of the second milestone payment to Giiant from the US Crohn’s and Colitis Foundation, through its Inflammatory Bowel Disease Ventures program.
-
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
12/28/2023
Pasithea Therapeutics Corp. announced that its meeting of stockholders, which had been partially adjourned on December 19, 2023, was reconvened on December 28, 2023 and then was further adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the charter amendment proposals included as Proposals 4, 5, 5 and 5 in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on October 26, 2023.
-
Calliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium Capital
12/27/2023
Calliditas Therapeutics AB and announced that the company has signed and fully drawn a term loan of 92 million Euros with funds managed by Athyrium Capital Management, LP.
-
Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9
12/27/2023
Scinai Immunotherapeutics Ltd., a biopharmaceutical company focused both on development of inflammation and immunology biological products and provision of boutique CDMO services, announced that the Company will host an analyst and investors webinar event on January 9, 2024.
-
McKesson Corporation Announces Third Quarter Fiscal 2024 Earnings Release Date and Participation in January Conference
12/27/2023
McKesson Corporation will release its third quarter fiscal 2024 financial results after market close on Wednesday, February 7, 2024.
-
First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced
12/27/2023
First Wave BioPharma, Inc. announced it has entered into agreements with certain holders of its existing warrants exercisable for 881,337 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $5.50 per share, in exchange for new warrants as described below.
-
Median Technologies Announces the Drawdown of €8.5m Corresponding to the Final Tranche of the European Investment Bank Loan
12/27/2023
Median Technologies announces that it has received approval from the European Investment Bank to draw down the final tranche of the loan granted on December 18, 2019, and renegotiated at the end of 2022.